Related Experiment Video
Updated: Jul 5, 2025

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
Published on: November 10, 2013
Cytotoxic Pt(II) complexes containing alizarin: a selective carrier for DNA metalation
Rossella Caligiuri1, Lara Massai2, Andrea Geri2
1MAT-INLAB, LASCAMM CR-INSTM, Unità INSTM della Calabria, Dipartimento di Chimica e Tecnologie Chimiche, Università della Calabria, Ponte Pietro Bucci Cubo 14C, Arcavacata di Rende (CS), 87036, Italy. iolinda.aiello@unical.it.
Abstract:
Many efforts have been made in the last few decades to selectively transport antitumor agents to their potential target sites with the aim to improve efficacy and selectivity. Indeed, this aspect could greatly improve the beneficial effects of a specific anticancer agent especially in the case of orphan tumors like the triple negative breast cancer. A possible strategy relies on utilizing a protective leaving group like alizarin as the Pt(II) ligand to reduce the deactivation processes of the pharmacophore enacted by Pt resistant cancer cells. In this study a new series of neutral mixed-ligand Pt(II) complexes bearing alizarin and a variety of diamine ligands were synthesized and spectroscopically characterized by FT-IR, NMR and UV-Vis analyses. Three Pt(II) compounds, i.e., 2b, 6b and 7b, emerging as different both in terms of structural properties and cytotoxic effects (not effective, 10.49 ± 1.21 μM and 24.5 ± 1.5 μM, respectively), were chosen for a deeper investigation of the ability of alizarin to work as a selective carrier. The study comprises the in vitro cytotoxicity evaluation against triple negative breast cancer cell lines and ESI-MS interaction studies relative to the reaction of the selected Pt(II) complexes with model proteins and DNA fragments, mimicking potential biological targets. The results allow us to suggest the use of complex 6b as a prospective anticancer agent worthy of further investigations.
Insights
Researchers developed new platinum(II) complexes with alizarin ligands to target triple-negative breast cancer. Complex 6b showed promising anticancer activity and selective targeting, warranting further investigation as a potential therapeutic agent.
Area of Science:
- Inorganic Chemistry
- Medicinal Chemistry
- Cancer Biology
Background:
- Selective drug delivery enhances anticancer agent efficacy, particularly for challenging cancers like triple-negative breast cancer.
- Platinum(II) complexes are investigated for cancer treatment, but resistance mechanisms can limit their effectiveness.
- Alizarin is explored as a protective ligand to improve the stability and targeting of platinum(II) pharmacophores.
Purpose of the Study:
- To synthesize and characterize novel neutral mixed-ligand platinum(II) complexes incorporating alizarin.
- To evaluate the in vitro cytotoxicity of these complexes against triple-negative breast cancer cell lines.
- To investigate the potential of alizarin as a selective carrier for platinum(II) anticancer agents.
Main Methods:
- Synthesis of platinum(II) complexes with alizarin and diamine ligands.
- Spectroscopic characterization using FT-IR, NMR, and UV-Vis analyses.
- In vitro cytotoxicity assays against triple-negative breast cancer cell lines.
- Electrospray ionization mass spectrometry (ESI-MS) studies to assess interactions with model proteins and DNA fragments.
Main Results:
- Three platinum(II) compounds (2b, 6b, 7b) exhibited varying cytotoxic effects.
- Complex 6b demonstrated significant cytotoxicity (10.49 ± 1.21 μM) against triple-negative breast cancer cells.
- ESI-MS studies provided insights into the interaction mechanisms of the complexes with biological targets.
Conclusions:
- Alizarin can function as a selective carrier for platinum(II) anticancer agents.
- Complex 6b shows potential as a prospective anticancer agent for triple-negative breast cancer.
- Further investigations into complex 6b are warranted for its therapeutic development.
More Related Videos
11:04Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
Published on: September 7, 2019
09:33Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
Related Concept Videos
Phase II Reactions: Miscellaneous Conjugation Reactions
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
EDTA: Auxiliary Complexing Reagents
Extraction: Advanced Methods